Potent in vitro synergistic antiviral effects of the pan-coronavirus fusion inhibitor EK1 in combination with RBD-specific antibodies or Mpro inhibitors - PubMed
6 hours ago
- #antiviral synergy
- #coronavirus therapy
- #viral evolution
- EK1, a pan-coronavirus fusion inhibitor, combined with RBD-specific antibodies or Mpro inhibitors shows synergistic antiviral effects against human coronaviruses including SARS-CoV-2 and HCoV-OC43.
- The multi-mechanistic therapy targets three distinct viral life cycle stages—receptor binding, membrane fusion, and viral replication—to reduce vulnerability to spike protein mutations.
- The strategy aims to raise the genetic barrier to resistance by targeting non-overlapping stages, offering potential against emerging variants and future outbreaks.
- Clinical translation requires optimizing delivery strategies due to differing pharmacokinetic profiles, but the study establishes a framework for trident anti-coronavirus therapy.